Posted by Michael Wonder on 30 Dec 2018
Adamis Pharmaceuticals submits new drug application to FDA for its tadalafil sublingual tablet
28 December 2018 - -- Adamis Pharmaceuticals today announced the submission of a new drug application to the U.S. FDA for its fast-dissolving sublingual tadalafil tablet.
This product candidate is designed for the treatment of erectile dysfunction. Adamis submitted the application pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.
